Mga Batayang Estadistika
| CIK | 1376339 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to MiMedx Group, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2025 MIMEDX GROUP, INC. |
|
| September 3, 2025 |
mimedxfiresidepptforcfco Cantor Global Healthcare Conference September 3, 2025 Investor Presentation Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| July 30, 2025 |
mimedxinvestorpresentati August 2025 Investor Presentation Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (Ex |
|
| July 30, 2025 |
q225mdxgccdeckvfinal Financial Results Conference Call July 30, 2025 Q2:2025 Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| July 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 30, 2025 MIMEDX GROUP, INC. |
|
| July 30, 2025 |
MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0. |
|
| July 28, 2025 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MiMedx Group, Inc. |
|
| July 28, 2025 |
As filed with the Securities and Exchange Commission on July 28, 2025 As filed with the Securities and Exchange Commission on July 28, 2025 Registration No. |
|
| July 28, 2025 |
Amendment to the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan (filed herewith). AMENDMENT TO THE MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN, AS AMENDED AND RESTATED WHEREAS, MiMedx Group, Inc., a Florida corporation (the “Company”) maintains the 2016 Equity and Cash Incentive Plan (as amended and restated, the “Plan”), the amendment and restatement of which was most recently adopted by the Company’s Board of Directors (the “Board”) on May 2, 2023 and approved by t |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2025 MIMEDX GROUP, INC. |
|
| May 23, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 13, 2025 MIMEDX GROUP, INC. |
|
| May 13, 2025 |
mimedxinvestorpresentati BofA Securities 2025 Health Care Conference May 2025 Investor Presentation Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| April 30, 2025 |
May 2025 Investor Presentation Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (E |
|
| April 30, 2025 |
Financial Results Conference Call April 30, 2025 Q1 2025 Disclaimer & Cautionary Statements This presentation and our earnings call includes forward-looking statements. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2025 MIMEDX GROUP, INC. |
|
| April 30, 2025 |
MIMEDX Announces First Quarter 2025 Operating and Financial Results Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0. |
|
| April 30, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| February 27, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2025 MIMEDX GROUP, INC. |
|
| February 27, 2025 |
February 2025 Investor Presentation Disclaimer & Cautionary Statements This presentation includes forward-looking statements. |
|
| February 26, 2025 |
Financial Results Conference Call February 26, 2025 Q4 & Full Year 2024 Disclaimer & Cautionary Statements Q4 & FY 2024 Financial Results Conference Call 2 This presentation includes forward-looking statements. |
|
| February 26, 2025 |
Key Employee Retention and Restrictive Covenant Agreement dated Ju Exhibit 10.46 RESTATED KEY EMPLOYEE RETENTION AND RESTRICTIVE COVENANT AGREEMENT THIS RESTATED KEY EMPLOYEE RETENTION AND RESTRICTIVE COVENANT AGREEMENT (the “Agreement”) is dated as of June 7, 2023 between MiMedx Group, Inc., a Florida corporation (the “Company”), and Kimberly Maersk-Moller (the “Executive”) (collectively, the Company and Executive referred to herein as the “Parties). WHEREAS, Co |
|
| February 26, 2025 |
Subsidiaries of MiMedx Group, Inc. Exhibit 21.1 MiMedx Group, Inc. List of Subsidiaries Company Jurisdiction of Organization MiMedx Tissue Services, LLC Georgia MiMedx Processing Services, LLC Florida MiMedx Supply, LLC Delaware MiMedx Japan, Godo Kaisha Japan |
|
| February 26, 2025 |
Offer Letter dated June 24, 2024 from MiMedx Group, Inc. to Kim Exhibit 10.45 Kim Moller [●] [●] Dear Kim: I am pleased to confirm your promotion to the position of Chief Commercial Officer (“CCO”) on behalf of MiMedx Group, Inc. (“MiMedx” or “Company”), effective June 24th, 2024, reporting directly to the Chief Executive Officer. In addition to your current responsibilities for all U.S. commercial sales and supporting functions, you will immediately assume re |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 26, 2025 MIMEDX GROUP, INC. |
|
| February 26, 2025 |
MIMEDX Announces Fourth Quarter and Full Year 2024 Operating and Financial Results Net Sales Grew 7% Year-Over-Year for the Fourth Quarter and 9% for the Full Year Fourth Quarter GAAP Net Income and Earnings Per Share were $7 million and $0. |
|
| February 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35887 MIMEDX GROUP, INC. (Exact nam |
|
| February 26, 2025 |
nsider Trading Policy dated January 6, 2025. Exhibit 19.1 MIMEDX GROUP, INC. INSIDER TRADING POLICY Policy Statement This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of MiMedx Group, Inc. (the “Company”) and the handling of confidential information about the Company and the companies with which the Company does business. The Company has adopted this Policy to promote compliance wit |
|
| January 14, 2025 |
Exhibit 99.1 Investor Presentation January 2025 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such forward-loo |
|
| January 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 14, 2025 MIMEDX GROUP, INC. |
|
| December 16, 2024 |
Form of Indemnification Agreement. Exhibit 10.1 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , between MIMEDX GROUP, INC., a Florida corporation (the “Company”), and (“Indemnitee”). WITNESSETH: WHEREAS, it is essential to the Company that it be able to retain and attract as officers and directors the most capable persons available; WHEREAS, increased corporate lit |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 11, 2024 MIMEDX GROUP, INC. |
|
| December 16, 2024 |
Lease Amendment dated December 11, 2024. Exhibit 10.2 FIFTH AMENDMENT TO LEASE AGREEMENT THIS FIFTH AMENDMENT TO LEASE AGREEMENT (the “Fifth Amendment”) is made as of December 11, 2024 (the “Effective Date”) by and between GEORGIA RE FIELDS, LLC, a Georgia limited liability company (the “Landlord”), and MIMEDX GROUP, INC., a Florida corporation (the “Tenant”), with reference to the following recitals: RECITALS: WHEREAS, HUB Properties, G |
|
| November 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 18, 2024 MIMEDX GROUP, INC. |
|
| November 18, 2024 |
EX-99.1 Investor Presentation November 2024 Exhibit 99.1 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such fo |
|
| November 7, 2024 |
MDXG / MiMedx Group, Inc. / Trigran Investments, Inc. - SC 13G Passive Investment SC 13G 1 tm2427429d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information Statement Pursuant to Rules 13d-1 Under the Securities Exchange Act of 1934 (Amendment No.)* MIMEDX GROUP, INC. (Name of Issuer) Common Stock, Par Value of $0.001 Per Share (Title of Class of Securities) 602496101 (CUSIP Number) August 30. 2024 Date o |
|
| November 7, 2024 |
EXHIBIT 1: Agreement to Make a Joint Filing EX-1 2 tm2427429d1ex1.htm EXHIBIT 1 CUSIP No. 602496101 Schedule 13G Page 1 of 1 Exhibit 1 EXHIBIT 1 TO SCHEDULE 13G November 7, 2024 In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, TRIGRAN INVESTMENTS, INC., DOUGLAS GRANAT, LAWRENCE A. OBERMAN, STEVEN G. SIMON, BRADLEY F. SIMON and STEVEN R. MONIESON each hereby agree to the joint filing of this statemen |
|
| October 30, 2024 |
Exhibit 99.3 Investor Presentation November 2024 helping humans heal. Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward- looking state |
|
| October 30, 2024 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2024 MIMEDX GROUP, INC. |
|
| October 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC |
|
| October 30, 2024 |
Exhibit 99.1 MIMEDX Announces Third Quarter 2024 Operating and Financial Results Net Sales of $84 million Grew 3% Year-Over-Year for the Third Quarter Third Quarter GAAP Net Income and Earnings Per Share were $8 Million and $0.05, Respectively Third Quarter Adjusted EBITDA was $18 Million, or 22% of Net Sales Raises 2024 Net Sales Growth Expectations to the High Single-Digits Management to Host Co |
|
| October 30, 2024 |
Exhibit 99.2 Q3 2024 Results Conference Call October 30, 2024 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward- looking statements. S |
|
| July 31, 2024 |
Exhibit 99.3 Investor Presentation August 2024 helping humans heal. Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statemen |
|
| July 31, 2024 |
Exhibit 99.1 MIMEDX Announces Second Quarter 2024 Operating and Financial Results Net Sales of $87 Million Grew 7% Year-Over-Year for the Second Quarter Second Quarter GAAP Net Income and Earnings Per Share were $18 Million and $0.12, Respectively Second Quarter Adjusted EBITDA was $20 Million, or 23% of Net Sales Management to Host Conference Call Today, July 31, 2024, at 4:30 PM ET MARIETTA, Ga. |
|
| July 31, 2024 |
Exhibit 99.2 Q2 2024 Results Conference Call July 31, 2024 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 31, 2024 MIMEDX GROUP, INC. |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (Ex |
|
| June 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 5, 2024 MIMEDX GROUP, INC. |
|
| May 24, 2024 |
May 24, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance, Office of Industrial Applications and Services 100 F Street, NE Washington, DC 20549 Attention: Julie Sherman Michael Fay Re: MIMEDX GROUP, INC. |
|
| April 30, 2024 |
EXHIBIT 10.2 MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Amended and Restated through May 2, 2023 Form of Performance Stock Unit Agreement THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of , between MIMEDX Group, Inc. (the “Company”) and (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, a |
|
| April 30, 2024 |
EXHIBIT 10.4 Execution Version CREDIT AGREEMENT dated as of January 19, 2024 among MIMEDX GROUP, INC., as the Borrower, THE LENDERS PARTY HERETO, CITIZENS BANK, N.A., as Administrative Agent, and BANK OF AMERICA, N.A., as Syndication Agent CITIZENS BANK, N.A. and BANK OF AMERICA, N.A. as Joint Lead Arrangers and Joint Bookrunners 4880-7517-6849 v.10 TABLE OF CONTENTS Page SCHEDULES: Schedule 2.1 C |
|
| April 30, 2024 |
EXHIBIT 10.1 MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Amended and Restated through May 2, 2023 Form of Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) dated as of the 202, between MiMedx Group, Inc. (the “Company”) and Participant Name (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and |
|
| April 30, 2024 |
Exhibit 99.3 Investor Presentation May 2024 helping humans heal. Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 30, 2024 MIMEDX GROUP, INC. |
|
| April 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (E |
|
| April 30, 2024 |
Exhibit 99.2 Q1 2024 Results Conference Call April 30, 2024 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such |
|
| April 30, 2024 |
Form 10-Q filed on April 30, 2024 EXHIBIT 10.3 MIMEDX GROUP, INC. Form of Nonqualified Stock Option Agreement THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated as of (the “Date of Grant”), between MiMedx Group, Inc. (the “Company”), and (the “Participant”), is made pursuant and subject to the provisions of the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through May 2, 2023 (the “ |
|
| April 30, 2024 |
Exhibit 99.1 MIMEDX Announces First Quarter 2024 Operating and Financial Results Net Sales of $85 Million Grew 18% Year-Over-Year for the First Quarter First Quarter GAAP Net Income was $9 Million First Quarter Adjusted EBITDA of $19 Million, or 22% of Net Sales Management to Host Conference Call Today, April 30, 2024, at 4:30 PM ET MARIETTA, Ga., April 30, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) |
|
| April 23, 2024 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| April 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ☒ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 27, 2024 MIMEDX GROUP, INC. |
|
| March 27, 2024 |
MIMEDX Provides Update on AXIOFILL® Request for Designation (“RFD”) from FDA Receives Determination Letter from FDA Stating AXIOFILL Does Not Qualify for Classification as an HCT/P Under Section 361 MIMEDX Continues to Pursue All Available Options to Keep AXIOFILL on the Market Reiterates Expectations for 2024 Net Sales Percentage Growth in the Low Double Digits and 2024 Adjusted EBITDA1 Margin Above 20% MARIETTA, Ga. |
|
| March 4, 2024 |
MIMEDX Announces Appointment of Two New Independent Directors MIMEDX Announces Appointment of Two New Independent Directors MARIETTA, Ga., March 4, 2024 - MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced the appointments of Tiffany Olson and Dorothy Puhy to its Board of Directors, effective as of March 1, 2024. Ms. Olson and Ms. Puhy each bring extensive and relevant experience across the healthcare industry, with demonstrated re |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 29, 2024 MIMEDX GROUP, INC. |
|
| February 28, 2024 |
incorporated by reference to Exhibit 97.1 to the Registrant’s Annual Report on Form 10-K filed on Compensation Recoupment Policy Amended and Restated November 29, 2023 Purpose: The Board of Directors (the “Board”) of MiMedx Group, Inc. |
|
| February 28, 2024 |
Exhibit 99.1 MIMEDX Announces Fourth Quarter and Full Year 2023 Operating and Financial Results Net Sales Grew 17% Year-Over-Year for the Fourth Quarter and 20% for the Full Year Fourth Quarter Net Income was $53 million, Inclusive of a $40 million One-Time Non-Cash Tax Benefit Fourth Quarter Adjusted EBITDA of $21 million, or 24% of Net Sales Management to Host Conference Call Today, February 28, |
|
| February 28, 2024 |
Subsidiaries of MiMedx Group, Inc. Exhibit 21.1 MiMedx Group, Inc. List of Subsidiaries Company Jurisdiction of Organization MiMedx Tissue Services, LLC Georgia MiMedx Processing Services, LLC Florida MiMedx Supply, LLC Delaware MiMedx Japan, Godo Kaisha Japan |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2024 MIMEDX GROUP, INC. |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35887 MIMEDX GROUP, INC. (Exact nam |
|
| February 28, 2024 |
Management Incentive Plan I.Purpose The Management Incentive Plan (“MIP”) is designed to provide an incentive for key members of the MiMedx Group, Inc. (“MiMedx” or “Company”) management team to exceed the annual corporate objectives and reward those team members with deserving performance. The MiMedx Board of Directors (the “Board of Directors”) has complete authority to interpret the MIP, to pre |
|
| February 28, 2024 |
(incorporated by reference to Exhibit 10.2D to FOURTH AMENDMENT TO LEASE AGREEMENT THIS FOURTH AMENDMENT TO LEASE AGREEMENT (the “Fourth Amendment”) is made as of January 26, 2024 (the “Effective Date”) by and between GEORGIA RE FIELDS, LLC, a Georgia limited liability company (the “Landlord”), and MIMEDX GROUP, INC. |
|
| February 28, 2024 |
(incorporated by reference to Exhibit 10.2 August 29, 2018 By FedEx Overnight Georgia RE Fields, LLC 521 NE Spanish Trail Boca Raton, FL 33432 Attn: Kim B. |
|
| February 28, 2024 |
Exhibit 99.2 Q4 & Full Year 2023 Results Conference Call February 28, 2024 helping humans heal. Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in |
|
| February 13, 2024 |
MDXG / MiMedx Group, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv01463-mimedxgroupinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: MiMedx Group Inc Title of Class of Securities: Common Stock CUSIP Number: 602496101 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate th |
|
| January 22, 2024 |
EX-99.1 Exhibit 99.1 MIMEDX Announces Improved Capital Structure with New Senior Secured Credit Facilities and Debt Refinancing New Credit Facilities Provide Substantial Interest Savings and Access to Additional Capital to Support Execution of Strategic Priorities MARIETTA, Ga., January 22, 2024 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it has enhanced it |
|
| January 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2024 MIMEDX GROUP, INC. |
|
| December 28, 2023 |
MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock Exhibit 99.1 MIMEDX Announces Conversion of Outstanding Series B Convertible Preferred Stock to Common Stock MARIETTA, Ga., December 28, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that its outstanding 95,000 shares of Series B Convertible Preferred Stock (the “Preferred Stock”), together with any accrued dividends, were automatically converted into shares |
|
| December 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 22, 2023 MIMEDX GROUP, INC. |
|
| December 27, 2023 |
MDXG / MiMedx Group, Inc. / Falcon Fund 2 Holding Company, L.P. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) MiMedx Group, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 602496101 (CUSIP Number) Martin P. Sutter Falcon Fund 2 Holding Company, L.P. 21 Waterway Avenue, Suite 225 The Woodlands, Texas 77380 (281) 364-1555 (Name, Address a |
|
| December 27, 2023 |
Joint Filing Agreement, dated December 27, 2023. EX-99.1 Exhibit 1 JOINT FILING AGREEMENT Each of the undersigned agrees that (i) the statement on Schedule 13D relating to the Common Stock of MiMedx Group, Inc., has been adopted and filed on behalf of each of them, (ii) all future amendments to such statement on Schedule 13D will, unless written notice to the contrary is delivered as described below, be jointly filed on behalf of each of them, a |
|
| November 13, 2023 |
MIMEDX to Participate in Upcoming Investor Conferences EX-99.1 Exhibit 99.1 MIMEDX to Participate in Upcoming Investor Conferences MARIETTA, Ga., November 13, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum Capital Group 14th Annual Alpha Select Conference Thursday, November 16, 2023 Sheraton New York Times Sq |
|
| November 13, 2023 |
EX-99.2 Exhibit 99.2 Investor Presentation November 2023 H E L P I N G H U M A N S H E A L Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the f |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 13, 2023 MIMEDX GROUP, INC. |
|
| October 30, 2023 |
Exhibit 99.1 MIMEDX Announces Third Quarter 2023 Operating and Financial Results Third Consecutive Quarter of Net Sales Growth Exceeding 20% Over the Prior Year Period Raises Full-Year 2023 Net Sales Percentage Growth Outlook to the High Teens MARIETTA, GA., October 30, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the thi |
|
| October 30, 2023 |
Separation Agreement and General Release between MiMedx Group, Inc. and Robert Stein June 20, 2023 Robert Stein [***] Re: Confidential Separation Agreement and General Release Dear Bob, As discussed, your employment relationship with MIMEDX Group, Inc. |
|
| October 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC |
|
| October 30, 2023 |
SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the “Agreement”) is hereby entered into by and between Peter Carlson (“Employee”) and MIMEDX Group, Inc. |
|
| October 30, 2023 |
Regulation FD Disclosure, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 30, 2023 MIMEDX GROUP, INC. |
|
| October 30, 2023 |
Exhibit 99.2 Q3:23 Results Conference Call October 30, 2023 HELPING HUMANS HEAL Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-look |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 5, 2023 MIMEDX GROUP, INC. |
|
| September 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 5, 2023 MIMEDX GROUP, INC. |
|
| September 5, 2023 |
EX-99.2 Exhibit 99.2 Investor Presentation September 2023 HELPING HUMANS HEAL Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-lookin |
|
| September 5, 2023 |
MIMEDX to Present at Upcoming Investor Conferences Exhibit 99.1 MIMEDX to Present at Upcoming Investor Conferences MARIETTA, Ga., September 5, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the following investor conferences: H.C. Wainwright 25th Annual Global Investment Conference Presentation: Tuesday, September 12, 2023 at 12:30 PM ET Webcast: Click here to access |
|
| August 1, 2023 |
EX-99.1 Exhibit 99.1 MIMEDX Announces Second Quarter 2023 Operating and Financial Results Records Second Quarter Net Sales of $81.3 Million; an Increase of 21.5% Over the Prior Year Period Increases Full-Year 2023 Guidance for Net Sales Growth Welcomes Highly Successful MedTech Executive as Chief Financial Officer Management to Host Conference Call on Tuesday, August 1, 2023, at 5:00 PM ET MARIETT |
|
| August 1, 2023 |
EX-99.2 Exhibit 99.2 Q2:23 Results Conference Call August 1, 2023 H E L P I N G H U M A N S H E A L Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (Ex |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 1, 2023 MIMEDX GROUP, INC. |
|
| August 1, 2023 |
Amendment No. 2 to Loan Agreement dated as of June 15, 2023 AMENDMENT NO. 2 TO LOAN AGREEMENT THIS AMENDMENT NO. 2 TO LOAN AGREEMENT (this “Amendment”), is made and entered into as of June 15, 2023, by and among MIMEDX GROUP, INC., a Delaware corporation (the “Borrower”), the Guarantors, the Lenders party hereto (who, as of the date hereof, constitute all Lenders) and HAYFIN SERVICES LLP (in its individual capacity, “HFS”), as administrative agent for the |
|
| July 25, 2023 |
Filing Fee Table (filed herewith). EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MiMedx Group, Inc. |
|
| July 25, 2023 |
Filing Fee Table (filed herewith). EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MiMedx Group, Inc. |
|
| July 25, 2023 |
As filed with the Securities and Exchange Commission on July 25, 2023 Form S-8 As filed with the Securities and Exchange Commission on July 25, 2023 Registration No. |
|
| July 25, 2023 |
As filed with the Securities and Exchange Commission on July 25, 2023 Form S-8 As filed with the Securities and Exchange Commission on July 25, 2023 Registration No. |
|
| July 5, 2023 |
KEY EMPLOYEE RETENTION AND RESTRICTIVE COVENANT AGREEMENT THIS KEY EMPLOYEE RETENTION AND RESTRICTIVE COVENANT AGREEMENT (the “Agreement”) is dated as of July 5, 2023 between MiMedx Group, Inc. |
|
| July 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 5, 2023 MIMEDX GROUP, INC. |
|
| July 5, 2023 |
MIMEDX GROUP, INC. Nonqualified Stock Option Agreement THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated as of the 30th day of June, 2023 (the “Date of Grant”), between MiMedx Group, Inc. (the “Company”), and Doug Rice (the “Participant”). This Option has not been granted under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through June, 2023 (t |
|
| July 5, 2023 |
MIMEDX GROUP, INC. Performance Stock Unit Agreement THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of the 30th day of June, 2023, between MiMedx Group, Inc. (the “Company”) and Doug Rice (the “Participant”). The Performance Stock Units have not been granted under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through June, 2023 (the “Plan”), |
|
| July 5, 2023 |
MIMEDX Appoints Doug Rice as Chief Financial Officer Company adds seasoned MedTech CFO to leadership team MARIETTA, Ga. |
|
| July 5, 2023 |
Doug Rice [***] Dear Doug: I am pleased to confirm our offer of employment to you for the position of Chief Financial Officer (“CFO”) on behalf of MiMedx Group, Inc. |
|
| July 5, 2023 |
MIMEDX GROUP, INC. Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this “Agreement”) dated as of the 30th day of June, 2023, between MiMedx Group, Inc. (the “Company”) and Doug Rice (the “Participant”). The Restricted Stock Units have not been granted under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated through June, 2023 (the “Plan”), and |
|
| June 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 MIMEDX GROUP, INC. |
|
| June 20, 2023 |
ex991june2023investorann Exhibit 99.1 MIMEDX Announces Strategic Realignment: Increases Focus on Wound & Surgical Business Expected to Significantly Improve Profitability Suspending Current Activities Associated with Knee Osteoarthritis Program and Disbanding Regenerative Medicine Business Unit Restructuring Expected to Generate Approximately $25 Million in Annualized Savings Raising Expectations |
|
| June 20, 2023 |
ex992juneinvestorcalldec HELPING HUMANS HEAL Investor Conference Call June 20, 2023 Exhibit 99. |
|
| June 14, 2023 |
ARTICLES OF AMENDMENT TO THE RESTATED ARTICLES OF INCORPORATION OF MIMEDX GROUP, INC. |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2023 MIMEDX GROUP, INC. |
|
| June 14, 2023 |
MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Amended and Restated through May 2, 2023 TABLE OF CONTENTS Page ARTICLE I DEFINITIONS 1 1.01 409A Award 1 1.02 Affiliate 1 1.03 Agreement 1 1.04 Award 1 1.05 Board 1 1.06 Cause 1 1.07 Change in Control 2 1.08 Code 3 1.09 Committee 3 1.10 Common Stock 3 1.11 Company 3 1.12 Control Change Date 3 1.13 Corresponding SAR 4 1.14 Disability 4 1.15 Di |
|
| May 15, 2023 |
TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ☒ Filed by a party other than the registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material Pursuant to §240. |
|
| May 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to §240. |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 2, 2023 MIMEDX GROUP, INC. |
|
| May 2, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (E |
|
| May 2, 2023 |
EX-99.2 Exhibit 99.2 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Q1:23 Results Conference Call May 2, 2023 Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 19 |
|
| May 2, 2023 |
EX-99.1 Exhibit 99.1 MIMEDX Announces First Quarter 2023 Operating and Financial Results First Quarter Net Sales of $71.7 Million Reflect an Increase of 21.7% Over the Prior Year Period Revenue Growth & Cost Controls Help Drive Improvements in Net Loss, EBITDA & Adjusted EBITDA1 Management to Host Conference Call on Tuesday, May 2, 2023, at 5:00 PM ET MARIETTA, Ga., May 2, 2023 — MiMedx Group, Inc |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (AMENDMENT NO. 1) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35887 MIMEDX GR |
|
| March 24, 2023 |
MIMEDX Announces Chief Financial Officer Transition Executive Search Underway EX-99.1 Exhibit 99.1 MIMEDX Announces Chief Financial Officer Transition Executive Search Underway MARIETTA, Ga., March 23, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, today announced that Peter M. Carlson, Chief Financial Officer, has decided to leave the Company to pursue other opportunities. The Company has initiated a searc |
|
| March 24, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 23, 2023 MIMEDX GROUP, INC. |
|
| March 9, 2023 |
Powers of Attorney (included on signature page hereto). Form S-8 As filed with the Securities and Exchange Commission on March 9, 2023 Registration No. |
|
| March 9, 2023 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MiMedx Group, Inc. |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2023 MIMEDX GROUP, INC. |
|
| February 28, 2023 |
EX-99.1 Exhibit 99.1 MIMEDX Announces Fourth Quarter and Full Year 2022 Operating and Financial Results Reports Highest Quarterly Net Sales Since the Fourth Quarter of 2019 Quarterly Net Sales of $74.4 million Reflect Growth of 10% with Strong Contributions from Sales to the Surgical Market Initiated the First of Two Registrational Clinical Trials for micronized dehydrated human amnion/chorion mem |
|
| February 28, 2023 |
EX-99.2 Exhibit 99.2 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Q4:22 & Full Year 2022 Results Conference Call February 28, 2023 Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute forward-looking statements within the meaning of the Private Securities Liti |
|
| February 28, 2023 |
EXHIBIT 10.4 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is the type that the registrant treats as private or confidential. PLATFORM INTELLECTUAL PROPERTY LICENSE AGREEMENT THIS PLATFORM INTELLECTUAL PROPERTY LICENSE (the “Agreement”), effective as of the 30th day of November 2022 (the “Effe |
|
| February 28, 2023 |
Subsidiaries of MiMedx Group, Inc. Exhibit 21.1 MiMedx Group, Inc. List of Subsidiaries Company Jurisdiction of Organization MiMedx Tissue Services, LLC Georgia MiMedx Processing Services, LLC Florida MiMedx Japan, Godo Kaisha Japan |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35887 MIMEDX GROUP, INC. (Exact nam |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 16, 2023 MIMEDX GROUP, INC. |
|
| February 23, 2023 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF MIMEDX GROUP, INC. ARTICLE I Corporate Offices Section 1. Principal and Registered Offices. The principal office of MiMedx Group, Inc. (the “Corporation”) shall be located at such place as the Board of Directors may specify from time to time. The Corporation shall have and continuously maintain a registered office and registered agent in accordance |
|
| February 23, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF MIMEDX GROUP, INC. ARTICLE I Corporate Offices Section 1. Principal and Registered Offices. The principal office of MiMedx Group, Inc. (the “Corporation”) shall be located at such place as the Board of Directors may specify from time to time. The Corporation shall have and continuously maintain a registered office and registered agent in accordance |
|
| February 9, 2023 |
MDXG / MiMedx Group Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SC 13G 1 tv01430-mimedxgroupinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: MiMedx Group Inc. Title of Class of Securities: Common Stock CUSIP Number: 602496101 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to whic |
|
| January 30, 2023 |
EX-10.3 Exhibit 10.3 MIMEDX GROUP, INC. Performance Stock Unit Agreement THIS PERFORMANCE STOCK UNIT AGREEMENT (this “Agreement”) dated as of the 27th day of January, 2023, between MiMedx Group, Inc. (the “Company”) and Joseph H. Capper (the “Participant”). The Performance Stock Units have not been granted under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and restated th |
|
| January 30, 2023 |
EX-10.4 Exhibit 10.4 MIMEDX GROUP, INC. Nonqualified Stock Option Agreement THIS NONQUALIFIED STOCK OPTION AGREEMENT (this “Agreement”) dated as of the 27th day of January, 2023 (the “Date of Grant”), between MiMedx Group, Inc. (the “Company”), and Joseph H. Capper (the “Participant”). This Option has not been granted under the MiMedx Group, Inc. 2016 Equity and Cash Incentive Plan, as amended and |
|
| January 30, 2023 |
Key Employee Retention Agreement EX-10.2 3 d456121dex102.htm EX-10.2 Exhibit 10.2 KEY EMPLOYEE RETENTION AGREEMENT THIS KEY EMPLOYEE RETENTION AGREEMENT (the “Agreement”) is dated as of January 27, 2023 between MiMedx Group, Inc., a Florida corporation (the “Company”), and Joseph H. Capper (the “Executive”) (collectively, the Company and Executive referred to herein as the “Parties). WHEREAS, the Company has determined that it is |
|
| January 30, 2023 |
EX-10.1 Exhibit 10.1 January 27, 2023 Joseph H. Capper [***] [***] Dear Joe: I am pleased to confirm in this letter (the “Letter Agreement”) our offer of employment to you for the position of Chief Executive Officer of MiMedx Group, Inc. (“MiMedx” or “Company”), subject to terms and conditions of this Letter Agreement. Your employment is to commence immediately with your first full day of employme |
|
| January 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 27, 2023 MIMEDX GROUP, INC. |
|
| January 30, 2023 |
MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director EX-99.1 6 d456121dex991.htm EX-99.1 Exhibit 99.1 MIMEDX Appoints Joseph H. Capper as Chief Executive Officer and Director Highly experienced and accomplished three-time healthcare CEO with a proven track record of substantial value creation to lead MIMEDX MARIETTA, Ga., January 30, 2023 — MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a pioneer and leader in placental biologics, to |
|
| January 9, 2023 |
EX-99.1 2 d442188dex991.htm EX-99.1 Investor Presentation January 2023 Exhibit 99.1 Disclaimer & Cautionary Statements Some of the information and statements contained in this presentation and certain oral statements made from time to time by representatives of MIMEDX constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that do not dire |
|
| January 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 MIMEDX GROUP, INC. |
|
| January 9, 2023 |
Exhibit 99.2 MIMEDX Confirms Fourth Quarter and Full Year 2022 Net Sales Expectations, Comments on Evolving Medicare Reimbursement Landscape and Provides Corporate Updates Fourth quarter and full year 2022 net sales expected in the ranges of $73 million to $76 million and $266 million to $269 million, respectively Provides commentary regarding the potential impact of recently published Medicare re |
|
| January 3, 2023 |
Exhibit 99.1 MIMEDX Appoints Ricci S. Whitlow as Chief Operating Officer MIMEDX bolsters management team with 30+ year MedTech veteran with extensive operational leadership MARIETTA, Ga., January 3, 2023 ? MiMedx Group, Inc. (Nasdaq: MDXG) (?MIMEDX? or the ?Company?), a pioneer and leader in placental biologics, today announced that it has appointed Ricci S. Whitlow as Chief Operating Officer, a r |
|
| January 3, 2023 |
Exhibit 10.1 Ricci Whitlow Leander, Texas 78641 Dear Ricci: I am pleased to confirm our offer of employment to you for the position of Chief Operating Officer (?COO?) on behalf of MiMedx Group, Inc. (?MiMedx? or ?Company?), which employment is to commence on or before January 3, 2023. In this position you will report directly to the Chief Executive Officer. Your initial base salary will be $20,769 |
|
| January 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2023 MIMEDX GROUP, INC. |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 13, 2022 MIMEDX GROUP, INC. |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 8, 2022 MIMEDX GROUP, INC. |
|
| November 30, 2022 |
Exhibit 99.1 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Investor Presentation November 2022 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the f |
|
| November 30, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 30, 2022 MIMEDX GROUP, INC. |
|
| November 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 17, 2022 MIMEDX GROUP, INC. |
|
| November 17, 2022 |
Exhibit 99.1 A PIONEER & LEADER IN PLACENTAL BIOLOGICS Investor Presentation November 2022 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the f |
|
| November 2, 2022 |
Exhibit 99.2 Q3:22 Financial Results November 2, 2022 1 Disclaimer & Cautionary Statements This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from those set forth in the forward-looking statements. Such for |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC |
|
| November 2, 2022 |
Exhibit 99.1 MIMEDX Announces Third Quarter 2022 Operating and Financial Results Third Quarter Net Sales of $67.7 Million Reflect Growth of 7.3% Introducing Wound & Surgical and Regenerative Medicine Segment Reporting to Highlight Trends Within Each Business Unit Third Quarter Growth Led by Surgical Recovery with Initial Contributions from AMNIOEFFECTTM and AXIOFILLTM Management to Host Conference |
|
| November 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2022 MIMEDX GROUP, INC. |
|
| September 16, 2022 |
by reference to Exhibit 10.1 to the Registrant’s Form 8-K filed EXHIBIT 10.1 INTERIM EXECUTIVE EMPLOYMENT AGREEMENT This Interim Executive Employment Agreement (?Agreement?) is effective as of September 14, 2022 (?Effective Date?), by and between MiMedx Group, Inc., a Florida corporation (the ?Company?), and K. Todd Newton, an individual (?Executive?). The Company and Executive are sometimes referred to as the ?Parties? or ?Party? in this Agreement. In conside |
|
| September 16, 2022 |
by reference to Exhibit 10.3 to the Registrant’s Form 8-K filed EXHIBIT 10.3 SEPARATION AGREEMENT AND GENERAL RELEASE This Separation Agreement and General Release (the ?Agreement?) is hereby entered into by and between Timothy R. Wright (?Employee?) and MiMedx Group, Inc. (?Company?). Employee and Company may be referred to herein individually as a ?Party? and collectively as the ?Parties.? WHEREAS, Company employed Employee most recently in the position of C |
|
| September 16, 2022 |
by reference to Exhibit 10.2 to the Registrant’s Form 8-K filed EXHIBIT 10.2 MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Amended and Restated through October 2, 2020 Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this ?Agreement?) dated as of the 15th day of September 2022, between MiMedx Group, Inc. (the ?Company?) and K. Todd Newton (the ?Participant?), is made pursuant and subject to the provisions of the Company?s 2016 Equ |
|
| September 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 14, 2022 MIMEDX GROUP, INC. |
|
| September 6, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 3, 2022 MIMEDX GROUP, INC. |
|
| September 6, 2022 |
mdxgleadershiptransition EXHIBIT 99.1 MIMEDX Announces Leadership Transition K. Todd Newton Appointed as Interim Chief Executive Officer, Replacing Timothy R. Wright, Effective Immediately MARIETTA, Ga., September 6, 2022 - MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), a transformational placental biologics company, today announced that K. Todd Newton, a member of the MIMEDX Board |
|
| August 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 10, 2022 MIMEDX GROUP, INC. |
|
| August 10, 2022 |
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Canaccord Genuity 42nd Annual Growth Conference August 2022 2 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. |
|
| August 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (Ex |
|
| August 2, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 2, 2022 MIMEDX GROUP, INC. |
|
| August 2, 2022 |
EXHIBIT 99.1 MIMEDX Announces Second Quarter 2022 Operating and Financial Results Second Quarter Net Sales of $66.9 Million Reflects Double-Digit Revenue Increase for the Fourth Consecutive Quarter in the Company's Continuing Portfolio of Products Achieves Strong Year-Over-Year Revenue Growth in Key Focus Area of Surgical Recovery Company Reaffirms 2022 Revenue Growth Outlook of 11% to 14% in Cont |
|
| June 30, 2022 |
Exhibit 99.1 June 30, 2022 Dear Shareholder, On behalf of the Board of Directors, I thank you for your support at our recent 2022 Annual Meeting of Shareholders. We value regular, candid and open shareholder engagement, and appreciate the constructive feedback received during the last months. We remain committed to working in your best interests. We have taken decisive action to successfully susta |
|
| June 30, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2022 MIMEDX GROUP, INC. |
|
| June 17, 2022 |
As filed with the Securities and Exchange Commission on June 17, 2022 As filed with the Securities and Exchange Commission on June 17, 2022 Registration No. |
|
| June 17, 2022 |
Filing Fee Table (filed herewith). Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) MiMedx Group, Inc. |
|
| June 15, 2022 |
MDXG / MiMedx Group Inc / Prescience Investment Group LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. )1 MiMedx Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 602496101 (CUSIP Number) June 1 |
|
| June 15, 2022 |
Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated June 15, 2022 (including amendments thereto) with respect to the shares of Common Stock, par value $0.001 per share, of MiMedx Group, Inc., and any further |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 7, 2022 MIMEDX GROUP, INC. |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| June 2, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| June 1, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| May 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant ? Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| May 24, 2022 |
A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY H.C. Wainwright Global Investment Conference May 2022 Exhibit 99.1 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ materially from t |
|
| May 24, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 24, 2022 MIMEDX GROUP, INC. |
|
| May 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| May 18, 2022 |
DEFA14A 1 a20220518defa14apressrelea.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ¨ Prelimi |
|
| May 18, 2022 |
DEFA14A 1 a20220518defa14awebsitedeck.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ¨ Prelim |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| May 16, 2022 |
DEFA14A 1 a20220516defa14awebsite.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ¨ Preliminar |
|
| May 13, 2022 |
DEFA14A 1 a20220513defa14ashareholde.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ¨ Prelimi |
|
| May 10, 2022 |
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Bank of America Securities Healthcare Conference May 2022 EXHIBIT 99. |
|
| May 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 10, 2022 MIMEDX GROUP, INC. |
|
| May 9, 2022 |
DEFA14A 1 a20220509defa14aemployeeme.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ¨ Check the appropriate box: ¨ Prelimi |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| May 9, 2022 |
MDXG / MiMedx Group Inc / Prescience Investment Group LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) (Amendment No. 1)1 MiMedx Group, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 602496101 (CUSIP Number) EIAD ASBAHI PRESCI |
|
| May 9, 2022 |
Exhibit 99.1 Prescience Point Capital Management Issues Open Letter to Shareholders of MiMedx Group Intends on Withholding Votes Against Directors Phyllis Gardner and James Bierman at 2022 Annual Meeting and Vote Against Approval of Executive Compensation BATON ROUGE, La., May 6, 2022 - Prescience Point Capital Management LLC (?Prescience Point?), a research-focused, catalyst-driven investment fir |
|
| May 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (E |
|
| May 3, 2022 |
EXHIBIT 99.1 MIMEDX Announces First Quarter 2022 Operating and Financial Results First Quarter Net Sales of $58.9 Million Reflects Double-Digit Revenue Increase for the Third Straight Quarter in the Company's Continuing Portfolio of Products Management to Host Conference Call on May 4, 2022, at 8:30 AM ET MARIETTA, Ga., May 3, 2022 - MiMedx Group, Inc. (Nasdaq: MDXG) (?MIMEDX? or the ?Company?), a |
|
| May 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 3, 2022 MIMEDX GROUP, INC. |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement x Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| April 29, 2022 |
MIMEDX Comments on Prescience Point’s Recent Filing Shareholders Urged to Support MIMEDX Board EXHIBIT 99.1 MIMEDX Comments on Prescience Point?s Recent Filing Shareholders Urged to Support MIMEDX Board MARIETTA, Ga. April 29, 2022 ? MIMEDX Group, Inc. (NASDAQ: MDXG) (?MIMEDX? or the ?Company?), a transformational placental biologics company, today issued the following statement in response to the filing of a Schedule 13D with the Securities and Exchange Commission by Prescience Point Capit |
|
| April 29, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 29, 2022 MIMEDX GROUP, INC. |
|
| April 28, 2022 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) Exhibit 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13D shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements. The undersigned ackn |
|
| April 28, 2022 |
MDXG / MiMedx Group Inc / Prescience Investment Group LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. )1 MiMedx Group, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 602496101 (CUSIP Number) EIAD ASBAHI PRESCIE |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 14A (Rule 14a-101) SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the registrant x Filed by a party other than the registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for use of the Commission only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement ? Definitive Additional Materials ? Soliciting Material Pursuant to ?240. |
|
| March 22, 2022 |
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Canaccord Genuity 2022 Musculoskeletal Conference March 22, 2022 EXHIBIT 99. |
|
| March 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 22, 2022 MIMEDX GROUP, INC. |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 28, 2022 MIMEDX GROUP, INC. |
|
| February 28, 2022 |
EXHIBIT 10.6 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (the ?Third Amendment?) is made as of November , 2021 (the ?Effective Date?) by and between GEORGIA RE FIELDS, LLC, a Georgia limited liability company (the ?Landlord?), and MIMEDX GROUP, INC., a Florida corporation (the ?Tenant?), with reference to the following recitals: RECITALS: WHEREAS, HUB Properties, GA, |
|
| February 28, 2022 |
Subsidiaries of MiMedx Group, Inc. Exhibit 21.1 MiMedx Group, Inc. List of Subsidiaries Company Jurisdiction of Organization MiMedx Tissue Services, LLC Georgia MiMedx Processing Services, LLC Florida |
|
| February 28, 2022 |
EX-99.1 2 ex9912021earningspressrele.htm EX-99.1 EXHIBIT 99.1 MIMEDX Announces Fourth Quarter and Full Year 2021 Operating and Financial Results Fourth Quarter Net Sales of $67.4 Million and Full Year 2021 Net Sales of $258.6 Million; Reflects a Double-Digit Revenue Increase in the Company's Continuing Portfolio of Products Vibrant Commercial Business is Funding New Product Development Initiatives |
|
| February 28, 2022 |
Amendment No. 1 to Loan Agreement dated as of February 28, 2022 Exhibit 10.38 AMENDMENT NO. 1 TO LOAN AGREEMENT THIS AMENDMENT NO. 1 TO LOAN AGREEMENT (this ?Amendment?), is made and entered into as of February 28, 2022, by and among MIMEDX GROUP, INC., a Delaware corporation (the ?Borrower?), the Guarantors, the Lenders party hereto (who, as of the date hereof, constitute all Lenders) and HAYFIN SERVICES LLP (in its individual capacity, ?HFS?), as administrat |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-35887 MIMEDX GROUP, INC. (Exact nam |
|
| February 8, 2022 |
MDXG / MiMedx Group Inc / Prescience Investment Group LLC - MIMEDX GROUP, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* MiMedx Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 602496101 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to |
|
| January 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 10, 2022 MIMEDX GROUP, INC. |
|
| January 10, 2022 |
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY 40th Annual J.P. Morgan Healthcare Conference January 2022 EXHIBIT 99.1 2 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ material |
|
| January 10, 2022 |
EXHIBIT 99.2 MIMEDX Outlines Key Strategic Milestones for 2022 MIMEDX Primed to Commence Pivotal Phase 3 Clinical Study Program of micronized dehydrated Human Amnion Chorion Membrane (mdHACM) in Knee Osteoarthritis (KOA), Targeting Potential Late-2026 Commercial Launch Double-Digit Growth Objective in 2022 to be Driven by Treatment Transformation, Global Market Expansion and Ongoing Portfolio Inno |
|
| December 7, 2021 |
EXHIBIT 99.2 MIMEDX Outlines Long-Term Value Creation Strategy at Virtual Investor Day Company to Share Probability Values from its Knee Osteoarthritis (KOA) Study; Analyses Conducted Support Confidence in Initiation of Confirmatory Phase 3 Trials in 2022 Commercial Business Strategy Demonstrates Sustainable Double-digit Growth Potential in Multiple Underpenetrated Markets MIMEDX Increases 2021 Ad |
|
| December 7, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 7, 2021 MIMEDX GROUP, INC. |
|
| December 7, 2021 |
EXHIBIT 99.3 December 7, 2021 Dear Shareholder: Earlier today, we hosted an exciting virtual Investor Day event with presentations from our executive team, key clinical opinion leaders and third-party experts. I hope you were able to listen in to hear the reasons behind our confidence in our planned Phase 3 Knee Osteoarthritis (KOA) clinical trial program, and the evident growth potential across o |
|
| December 7, 2021 |
1 A TRANSFORMATIONAL PLACENTAL BIOLOGICS COMPANY Investor Day December 7, 2021 EXHIBIT 99. |
|
| November 22, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 22, 2021 MIMEDX GROUP, INC. |
|
| November 22, 2021 |
1 ADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE 2021 Piper Sandler 33rd Annual Healthcare Conference November 2021 EXHIBIT 99. |
|
| November 2, 2021 |
EX-99.1 2 ex9913q2021earningspressre.htm EX-99.1 EXHIBIT 99.1 MIMEDX Announces Third Quarter 2021 Operating and Financial Results Third Quarter Net Sales of $63.1 Million Versus $64.3 Million in 3Q20 Adjusted Net Sales of $62.8 Million Include a 13% Increase in Core Portfolio Sales Versus 3Q20 Year-to-Date Adjusted Net Sales Increase of 16% in Core Portfolio Sales Versus Prior Year Period Reflects |
|
| November 2, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 2, 2021 MIMEDX GROUP, INC. |
|
| November 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC |
|
| September 13, 2021 |
1 ADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE Investor Presentation September 2021 2 DISCLAIMER & CAUTIONARY STATEMENTS This presentation includes forward-looking statements. |
|
| September 13, 2021 |
EXHIBIT 99.1 MIMEDX Reports Top-line Data from Two Late-Stage Musculoskeletal Trials with Proprietary Amniotic Tissue Technology Phase 2B Knee Osteoarthritis (KOA) Study Top-line Interim Results Demonstrate Varied Efficacy Signals between Patient Cohorts Company to Pursue Phase 3 KOA Confirmatory Studies Initial Review of Phase 3 Plantar Fasciitis Trial Data Does Not Support a Biologics License Ap |
|
| September 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 13, 2021 MIMEDX GROUP, INC. |
|
| September 2, 2021 |
September 2, 2021 VIA EDGAR United States Securities and Exchange Commission 100 F Street, NE Washington, D. |
|
| August 27, 2021 |
Specimen preferred stock certificate EX-4.7 3 d221110dex47.htm EX-4.7 Exhibit 4.7 INCORPORATED UNDER THE LAWS OF THE STATE OF FLORIDA MiMed IS THE RECORD HOLDER OF FITLY PAID AND NON ASSESSABLE SHARES OF SERIES BCONVERTIBLE INVERTIBLE PREFERRED STOCK PAR VALUE $0.001 EACH OF 11 TRANSFERABLE on the books o| the corporation by the holder hereof. in person on by duly authorized Attorney upon surrender this Certificate properly endorsed. |
|
| August 27, 2021 |
As filed with the Securities and Exchange Commission on August 27, 2021 Table of Contents As filed with the Securities and Exchange Commission on August 27, 2021 Registration No. |
|
| August 27, 2021 |
EX-4.11 4 d221110dex411.htm EX-4.11 Exhibit 4.11 MIMEDX GROUP, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 31 |
|
| August 27, 2021 |
Form of subordinated indenture Exhibit 4.12 MIMEDX GROUP, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE(1) Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) I |
|
| August 27, 2021 |
Specimen common stock certificate EX-4.6 2 d221110dex46.htm EX-4.6 Exhibit 4.6 INCORPORATED UNDER THE LAWS OF THE STATE OF FLORIDA CUSIP NO. b02496 10 1 MiMecb ™ SPECIMIN FULLY PAlD AND NON ASSESSABLE SHARES OF COMMON STOCK PAR VALUE $0.001 EACH OF MIMEDX GROUP, INC., TRANSFERABLE ON THE books of the corporation by the holder hereof, in person or by duly authorized B Attornen upon surrender o| this Certificate property properly en |
|
| August 3, 2021 |
Proposed Form of Initial Pro-rata Director RSU ? one year vest MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Non-Employee Director Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this "Agreement") dated as of the day of , 20 (the ?Grant Date?), between MiMedx Group, Inc. (the "Company") and (the "Participant"), is made pursuant and subject to the provisions of the Co |
|
| August 3, 2021 |
Proposed Form of Initial Director RSU ? three year vest MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Non-Employee Director Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this "Agreement") dated as of the day of 20 (the ?Grant Date?), between MiMedx Group, Inc. (the "Company") and (the "Participant"), is made pursuant and subject to the provisions of the Company's 2 |
|
| August 3, 2021 |
EXHIBIT 99.1 MIMEDX Announces Second Quarter 2021 Operating and Financial Results Second Quarter Net Sales Increase 27% to $68.2 million Versus Q2 2020 On Track to Deliver Topline Results for Late-Stage Musculoskeletal Pipeline in Late Summer Company to Host Conference Call on August 4, 2021, at 8:30 AM ET MARIETTA, Ga., August 3, 2021 - MiMedx Group, Inc. (Nasdaq: MDXG) (?MIMEDX? or the ?Company? |
|
| August 3, 2021 |
Exhibit 10.1 (as amended and restated as of June 30, 2021) Mr. Peter M. Carlson [**] Dear Pete, I am pleased to confirm our offer of employment to you for the position of Chief Financial Officer on behalf of MiMedx Group, Inc. (?MiMedx? or ?Company?), which employment is to commence on or around December 16, 2019. In this position, you will report directly to Timothy R. Wright, Chief Executive Off |
|
| August 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-35887 MIMEDX GROUP, INC. (Ex |
|
| August 3, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 3, 2021 MIMEDX GROUP, INC. |
|
| August 3, 2021 |
Proposed Form of Director RSU ? one year vest MIMEDX GROUP, INC. 2016 EQUITY AND CASH INCENTIVE PLAN Non-Employee Director Restricted Stock Unit Agreement THIS RESTRICTED STOCK UNIT AGREEMENT (this "Agreement") dated as of the day of , 20 (the ?Grant Date?), between MiMedx Group, Inc. (the "Company") and (the "Participant"), is made pursuant and subject to the provisions of the Company's 2016 Equi |
|
| July 13, 2021 |
MDXG / MiMedx Group Inc / Prescience Investment Group LLC - MIMEDX GROUP, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* MiMedx Group, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 602496101 (CUSIP Number) July 13, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| July 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 30, 2021 MIMEDX GROUP, INC. |
|
| June 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 23, 2021 MIMEDX GROUP, INC. |
|
| June 23, 2021 |
Exhibit 99.1 ADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE Raymond James Human Health Innovation Conference June 23, 2021 1Exhibit 99.1 ADVANCING REGENERATIVE MEDICINE TREATMENT THROUGH PLACENTAL SCIENCE Raymond James Human Health Innovation Conference June 23, 2021 1 DISCLAIMER & CAUTIONARY STATEMENTS Important Cautionary Statement This presentation includes forward-looking |
|
| June 10, 2021 |
Exhibit 3.2 ARTICLES OF AMENDMENT TO RESTATED ARTICLES OF INCORPORATION OF MIMEDX GROUP, INC. TO REDUCE OWNERSHIP THRESHOLD TO CALL A SPECIAL SHAREHOLDERS? MEETING FIRST: This Corporation is named MiMedx Group, Inc. (the ?Corporation?). The Articles of Incorporation of the Corporation were originally filed with the Office of the Department of State of the State of Florida on February 8, 2008. The |
|
| June 10, 2021 |
Exhibit 3.1 ARTICLES OF AMENDMENT TO RESTATED ARTICLES OF INCORPORATION OF MIMEDX GROUP, INC. TO DECLASSIFY THE BOARD OF DIRECTORS FIRST: This Corporation is named MiMedx Group, Inc. (the ?Corporation?). The Articles of Incorporation of the Corporation were originally filed with the Office of the Department of State of the State of Florida on February 8, 2008. The Restated Articles of Incorporatio |
|
| June 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 9, 2021 MIMEDX GROUP, INC. |
|
| June 3, 2021 |
Exhibit 3.1 AMENDMENT NO. 1 TO THE AMENDED AND RESTATED BYLAWS OF MIMEDX GROUP, INC. Pursuant to the resolutions duly adopted by the Board of Directors of MiMedx Group, Inc., a Florida corporation (the ?Corporation?), and in accordance with Section 10, Article VIII of the Amended and Restated Bylaws of the Corporation (the ?Bylaws?), the Bylaws are amended as set forth below. Except as specificall |
